

# Renato Bernardini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4676764/publications.pdf>

Version: 2024-02-01

88  
papers

2,938  
citations

230014

27  
h-index

206121

51  
g-index

96  
all docs

96  
docs citations

96  
times ranked

3859  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunotherapy of cancer in single-cell RNA sequencing era: A precision medicine perspective. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112558.	2.5	10
2	The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112516.	2.5	38
3	Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease. <i>Neurotherapeutics</i> , 2022, 19, 305-324.	2.1	3
4	Ampicillin plus ceftriaxone therapy against <i>Enterococcus faecalis</i> endocarditis: A case report, guidelines considerations, and literature review. <i>IDCases</i> , 2022, 28, e01462.	0.4	4
5	Intranasal Administration of a TRAIL Neutralizing Monoclonal Antibody Adsorbed in PLGA Nanoparticles and NLC Nanosystems: An In Vivo Study on a Mouse Model of Alzheimer's Disease. <i>Biomedicines</i> , 2022, 10, 985.	1.4	13
6	Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations. <i>Infectious Disease Reports</i> , 2022, 14, 360-371.	1.5	14
7	COVID Vaccination in Cancer Patients: What Vaccination Priority Strategies Should There Be?. <i>Frontiers in Oncology</i> , 2021, 11, 641388.	1.3	10
8	Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era. <i>Cancers</i> , 2021, 13, 1906.	1.7	6
9	Anti-malarial Drugs are Not Created Equal for SARS-CoV-2 Treatment: A Computational Analysis Evidence. <i>Current Pharmaceutical Design</i> , 2021, 27, 1323-1329.	0.9	0
10	In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 1013-1025.	2.6	6
11	Brimonidine is Neuroprotective in Animal Paradigm of Retinal Ganglion Cell Damage. <i>Frontiers in Pharmacology</i> , 2021, 12, 705405.	1.6	30
12	Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. <i>Biomedicines</i> , 2021, 9, 1075.	1.4	46
13	Stem Cells: Innovative Therapeutic Options for Neurodegenerative Diseases?. <i>Cells</i> , 2021, 10, 1992.	1.8	18
14	Beneficial Effects of Choline Alphoscerate on Amyloid- $\beta$ Neurotoxicity in an In vitro Model of Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2021, 18, 298-309.	0.7	2
15	The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10719.	1.8	36
16	Ampicillin Plus Ceftriaxone Regimen against <i>Enterococcus faecalis</i> Endocarditis: A Literature Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 4594.	1.0	25
17	Targeting the miRNA-155/TNFSF10 network restrains inflammatory response in the retina in a mouse model of Alzheimer's disease. <i>Cell Death and Disease</i> , 2021, 12, 905.	2.7	16
18	A Systematic Review on PD-1 Blockade and PD-1 Gene-Editing of CAR-T Cells for Glioma Therapy: From Deciphering to Personalized Medicine. <i>Frontiers in Immunology</i> , 2021, 12, 788211.	2.2	5

#	ARTICLE	IF	CITATIONS
19	The immune system on the TRAIL of Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2020, 17, 298.	3.1	42
20	On the Management of Drug Interactions in the Course of Concomitant Treatments for COVID-19 and Antineoplastic Agents. <i>Frontiers in Oncology</i> , 2020, 10, 1340.	1.3	3
21	Repositioning of Immunomodulators: A Ray of Hope for Alzheimer's Disease?. <i>Frontiers in Neuroscience</i> , 2020, 14, 614643.	1.4	16
22	We Really Need Clear Guidelines and Recommendations for Safer and Proper Use of Aripiprazole and Risperidone in a Pediatric Population: Real-World Analysis of EudraVigilance Database. <i>Frontiers in Psychiatry</i> , 2020, 11, 550201.	1.3	10
23	A multi-stakeholder approach in optimising patients' needs in the benefit assessment process of new metastatic breast cancer treatments. <i>Breast</i> , 2020, 52, 78-87.	0.9	7
24	Beneficial effects of curtailing immune susceptibility in an Alzheimer's disease model. <i>Journal of Neuroinflammation</i> , 2019, 16, 166.	3.1	27
25	Ocular Pharmacological Profile of Hydrocortisone in Dry Eye Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 1240.	1.6	27
26	The Biochemical and Pharmacological Properties of Ozone: The Smell of Protection in Acute and Chronic Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 634.	1.8	70
27	Tumor necrosis factor-related apoptosis-inducing ligand reduces the expression of the neuroprotective Na <sup>+</sup> /Ca <sup>2+</sup> exchanger isoform NCX 3 in human neuroblastoma SH-SY 5Y cells. <i>FEBS Journal</i> , 2019, 286, 737-749.	2.2	4
28	Weight-Change Trajectories of Pediatric Outpatients Treated with Risperidone or Aripiprazole in a Naturalistic Setting. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 133-140.	0.7	14
29	Functional Changes of Orexinergic Reaction to Psychoactive Substances. <i>Molecular Neurobiology</i> , 2018, 55, 6362-6368.	1.9	29
30	The Role of Anabolic Androgenic Steroids in Disruption of the Physiological Function in Discrete Areas of the Central Nervous System. <i>Molecular Neurobiology</i> , 2018, 55, 5548-5556.	1.9	38
31	Inhibition of aldose-reductase-2 by a benzofuroxane derivative bf-5m increases the expression of <i>kcne1</i> , <i>kcnq1</i> in high glucose cultured H9c2 cardiac cells and sudden cardiac death. <i>Oncotarget</i> , 2018, 9, 17257-17269.	0.8	6
32	Redundant modulatory effects of proinflammatory cytokines in human osteoblastic cells in vitro. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 959-969.	0.4	2
33	The efficacy of an association of palmitoylethanolamide and alpha-lipoic acid in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized clinical trial. <i>Archivio Italiano Di Urologia Andrologia</i> , 2017, 89, 17.	0.4	13
34	The Proinflammatory Cytokine GITRL Contributes to TRAIL-mediated Neurotoxicity in the HCN-2 Human Neuronal Cell Line. <i>Current Alzheimer Research</i> , 2017, 14, 1090-1101.	0.7	4
35	Remifentanyl and worse patient-reported outcomes regarding postoperative pain management after thyroidectomy. <i>Journal of Clinical Anesthesia</i> , 2016, 31, 27-33.	0.7	19
36	Second generation antipsychotics in "real-life" paediatric patients. Adverse drug reactions and clinical outcomes of drug switch. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1-8.	1.0	20

#	ARTICLE	IF	CITATIONS
37	Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 285-293.	0.8	21
38	Persistence in Therapy With Risperidone and Aripiprazole in Pediatric Outpatients. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1601-e1609.	1.1	14
39	Neutralization of TNFSF10 ameliorates functional outcome in a murine model of Alzheimer's disease. <i>Brain</i> , 2015, 138, 203-216.	3.7	62
40	Involvement of caspase-8 and caspase-FLIP in the proangiogenic effects of the tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). <i>FEBS Journal</i> , 2014, 281, 1505-1513.	2.2	13
41	CHF5074 Protects SH-SY5Y Human Neuronal-like Cells from Amyloidbeta 25-35 and Tumor Necrosis Factor Related Apoptosis Inducing Ligand Toxicity In Vitro. <i>Current Alzheimer Research</i> , 2014, 11, 714-724.	0.7	16
42	Nerve growth factor (NGF) levels in follicular fluid of infertile patients undergoing to in vitro fertilization (IVF) cycle. <i>Gynecological Endocrinology</i> , 2013, 29, 1002-1004.	0.7	9
43	Glutamate-Induced ATP Synthesis: Relationship between Plasma Membrane Na <sup>+</sup> /Ca <sup>2+</sup> Exchanger and Excitatory Amino Acid Transporters in Brain and Heart Cell Models. <i>Molecular Pharmacology</i> , 2013, 84, 603-614.	1.0	44
44	The antimitogenic effect of the cannabinoid receptor agonist WIN55212-2 on human melanoma cells is mediated by the membrane lipid raft. <i>Cancer Letters</i> , 2011, 310, 240-249.	3.2	21
45	Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. <i>Biochemical Pharmacology</i> , 2011, 82, 380-388.	2.0	74
46	Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 433-438.	2.6	34
47	Neutralization of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Reduces Spinal Cord Injury Damage in Mice. <i>Neuropsychopharmacology</i> , 2010, 35, 1302-1314.	2.8	30
48	Sorafenib: Rays of Hope in Thyroid Cancer. <i>Thyroid</i> , 2010, 20, 1351-1358.	2.4	19
49	The CB1/CB2 receptor agonist WIN-55,212-2 reduces viability of human Kaposi's sarcoma cells in vitro. <i>European Journal of Pharmacology</i> , 2009, 616, 16-21.	1.7	27
50	Amylin prevents TRAIL-mediated apoptotic effects of reserpine in the rat gastric mucosa. <i>Peptides</i> , 2009, 30, 1466-1472.	1.2	6
51	Symptomatic hypocalcemia in an epileptic child treated with valproic acid plus lamotrigine: a case report. <i>Cases Journal</i> , 2009, 2, 7394.	0.4	9
52	TRAIL-related neurotoxicity implies interaction with the Wnt pathway in human neuronal cells in vitro. <i>Journal of Neurochemistry</i> , 2008, 105, 1915-1923.	2.1	15
53	Recombinant human TNF-binding protein-1 (rhTBP-1) treatment delays both symptoms progression and motor neuron loss in the wobbler mouse. <i>Neurobiology of Disease</i> , 2008, 29, 465-476.	2.1	23
54	The role of antioxidant supplement in immune system, neoplastic, and neurodegenerative disorders: a point of view for an assessment of the risk/benefit profile. <i>Nutrition Journal</i> , 2008, 7, 29.	1.5	104

#	ARTICLE	IF	CITATIONS
55	Protective effects of the sigma agonist Pre-084 in the rat retina. <i>British Journal of Ophthalmology</i> , 2007, 91, 1382-1384.	2.1	29
56	Protective effects of amylin on reserpine-induced gastric damage in the rat. <i>Pharmacological Research</i> , 2007, 56, 27-34.	3.1	19
57	Trail interacts redundantly with nitric oxide in rat astrocytes: Potential contribution to neurodegenerative processes. <i>Journal of Neuroimmunology</i> , 2007, 182, 41-47.	1.1	23
58	Levels of matrix metalloproteinases 1 and 2 in human gingival crevicular fluid during initial tooth movement. <i>American Journal of Orthodontics and Dentofacial Orthopedics</i> , 2006, 130, 568.e11-568.e16.	0.8	43
59	Adrenomedullin modulates COX-2 and HGF expression in reserpine-injured gastric mucosa in the rat. <i>European Journal of Pharmacology</i> , 2005, 518, 221-226.	1.7	18
60	Effect of adrenomedullin on c-Met receptor expression after reserpine-induced gastric damage in the rat. <i>European Journal of Pharmacology</i> , 2004, 488, 219-224.	1.7	3
61	Role of Magnesium, Coenzyme Q10, Riboflavin, and Vitamin B12 in Migraine Prophylaxis. <i>Vitamins and Hormones</i> , 2004, 69, 297-312.	0.7	58
62	TRAIL is expressed in the brain cells of Alzheimer's disease patients. <i>NeuroReport</i> , 2004, 15, 579-581.	0.6	45
63	Synthesis of new P3CS derivatives and their mitogenic activity on in vitro mice splenocytes. <i>Il Farmaco</i> , 2003, 58, 329-336.	0.9	2
64	Essential pathogenic role of endogenous IL-18 in murine diabetes induced by multiple low doses of streptozotocin. Prevention of hyperglycemia and insulinitis by a recombinant IL-18-binding protein: Fc construct. <i>European Journal of Immunology</i> , 2003, 33, 2278-2286.	1.6	37
65	Growth hormone protects human lymphocytes from irradiation-induced cell death. <i>British Journal of Pharmacology</i> , 2003, 138, 1411-1416.	2.7	28
66	Psychoneuroendocrinological links between chronic stress and depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 893-903.	2.5	178
67	Nerve growth factor's endothelial cell interaction leads to angiogenesis in vitro and in vivo. <i>FASEB Journal</i> , 2002, 16, 1307-1309.	0.2	214
68	Increased ACTH and cortisol secretion after interleukin-1 $\beta$ injection in the common marmoset ( <i>Callithrix jacchus jacchus</i> ). <i>Life Sciences</i> , 2001, 68, 1657-1665.	2.0	3
69	Divergent effects of corticotropin releasing hormone on endothelial cell nitric oxide synthase are associated with different expression of CRH type 1 and 2 receptors. <i>British Journal of Pharmacology</i> , 2001, 134, 837-844.	2.7	30
70	Apomorphine, dopamine and phenylethylamine reduce the proportion of phosphorylated insulin receptor substrate 1. <i>European Journal of Pharmacology</i> , 2001, 433, 47-54.	1.7	11
71	Responsiveness of Irradiated Rat Anterior Pituitary Cells to Hypothalamic Releasing Hormones Is Restored by Treatment with Growth Hormone. <i>Neuroendocrinology</i> , 2000, 72, 392-399.	1.2	8
72	Synthesis and Immunostimulating Activity of A Thioglycolipopeptide Glycomimetic As A Potential Anticancer Vaccine Derived From Tn Antigen. <i>Journal of Carbohydrate Chemistry</i> , 2000, 19, 527-541.	0.4	44

#	ARTICLE	IF	CITATIONS
73	Mitogenic Effect of Nerve Growth Factor (NGF) in LNCaP Prostate Adenocarcinoma Cells: Role of the High- and Low-Affinity NGF Receptors. <i>Molecular Endocrinology</i> , 2000, 14, 124-136.	3.7	44
74	Dopamine agonists and analogues have an antiproliferative effect on CHO-K1 cells. <i>Neurotoxicity Research</i> , 1999, 1, 285-297.	1.3	7
75	Adenylate-Cyclase-Dependent Pituitary Adrenocorticotropin Secretion Is Defective in the Inflammatory-Disease-Susceptible Lewis Rat. <i>Neuroendocrinology</i> , 1996, 63, 468-474.	1.2	9
76	Is Side-Stream Smoke a Stressor?. <i>Indoor and Built Environment</i> , 1995, 4, 157-161.	1.5	0
77	In vivo and in vitro Effects of Arginine-Vasopressin Receptor Antagonists on the Hypothalamic-Pituitary-Adrenal Axis in the Rat. <i>Neuroendocrinology</i> , 1994, 60, 503-508.	1.2	25
78	Neurotransmitter-Induced Hypothalamic-Pituitary-Adrenal Axis Responsiveness Is Defective in Inflammatory Disease-Susceptible Lewis Rats: In vivo and in vitro Studies Suggesting Globally Defective Hypothalamic Secretion of Corticotropin-Releasing Hormone. <i>Neuroendocrinology</i> , 1992, 55, 600-608.	1.2	114
79	Plasma $\beta$ -endorphin levels and natural killer cells in two cases of congenital indifference to pain. <i>Child's Nervous System</i> , 1992, 8, 83-85.	0.6	4
80	Chronic Sodium or Chloride Depletion Upregulates Angiotensin II Receptors in the Anterior Pituitary Lobe of Young Rats. <i>Neuroendocrinology</i> , 1991, 53, 556-561.	1.2	3
81	Interactions between Tumor Necrosis Factor- $\beta$ , Hypothalamic Corticotropin-Releasing Hormone, and Adrenocorticotropin Secretion in the Rat*. <i>Endocrinology</i> , 1990, 126, 2876-2881.	1.4	222
82	Mediators of the inflammatory/immune response: Relevance to the hypothalamic-pituitary-adrenal axis. <i>Pharmacological Research</i> , 1990, 22, 46.	3.1	1
83	Rat hypothalamic corticotropin-releasing hormone secretion is stimulated by interleukin-1 in an eicosanoid-dependent manner. <i>Life Sciences</i> , 1990, 47, 1601-1607.	2.0	61
84	The Alkyl-Ether Phospholipid Platelet-Activating Factor is a Stimulator of the Hypothalamic-Pituitary-Adrenal Axis in the Rat*. <i>Endocrinology</i> , 1989, 125, 1067-1073.	1.4	44
85	Effects of serotonergic agonists and antagonists on corticotropin-releasing hormone secretion by explanted rat hypothalami. <i>Peptides</i> , 1989, 10, 189-200.	1.2	221
86	Arachidonic Acid Metabolites Modulate Rat Hypothalamic Corticotropin-Releasing Hormone Secretion in vitro. <i>Neuroendocrinology</i> , 1989, 50, 708-715.	1.2	81
87	Effect of Cholinergic Agonists and Antagonists on Rat Hypothalamic Corticotropin-Releasing Hormone Secretion in vitro. <i>Neuroendocrinology</i> , 1988, 47, 303-308.	1.2	92
88	Regulation of Rat Hypothalamic Corticotropin-Releasing Hormone Secretion in vitro: Potential Clinical Implications. <i>Advances in Experimental Medicine and Biology</i> , 1988, 245, 167-181.	0.8	37